PT  - JOURNAL ARTICLE
AU  - Kawada, Tomoyuki
TI  - Febuxostat Use and Safety in Patients With Hyperuricemia
AID  - 10.3899/jrheum.220147
DP  - 2022 Jun 15
TA  - The Journal of Rheumatology
PG  - jrheum.220147
4099  - http://www.jrheum.org/content/early/2022/06/09/jrheum.220147.short
4100  - http://www.jrheum.org/content/early/2022/06/09/jrheum.220147.full
AB  - I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57–1.32).